Table 1 Clinical features of cystic fibrosis patients included in the study
From: Genetic interaction of GSH metabolic pathway genes in cystic fibrosis
Sex (male) | 50% (80)# |
Age | 17.72 ± 15.75 years (0.6 – 24 years)* |
BMI - thinness and accentuated thinness | 22.22% (40)# |
One Class I. II or III identified mutation | 28.33% (51)# |
Two Class I. II or III identified mutation | 47.22% (85)# |
First clinical manifestation | 2.90 ± 8.89 years (0 – 13 years)* |
Age at diagnosis | 7.62 ± 13.63 years (0 – 14.23 years)* |
Onset of digestive symptoms | 3.39 ± 9.11 years (0 – 12.45 years)* |
Onset of pulmonary symptoms | 2.90 ± 9.89 years (0 – 13 years)* |
SpO2 | 94.92 ± 4.26 (66 – 99)* |
Bhalla score | 8.74 ± 5.724 (0 – 25)* |
Kanga score | 18.85 ± 5.84 (10 – 40)* |
Shwachman-Kulczycki score | 65.85 ± 16.77 (20 – 95)* |
FVC (%) | 79.29 ± 23.55 (19 – 135)* |
FEV1 (%) | 71.29 ± 27.47 (17 – 132)* |
FEV1/FVC (%) | 83.46 ± 15.95 (37 – 137)* |
FEF25-75% | 59.05 ± 35.55 (7 – 150)* |
Nasal Polyps | 18.33% (33)# |
Diabetes mellitus | 18.33% (33)# |
Osteoporosis | 16.11% (29)# |
Pancreatic insufficiency | 80.0% (144)# |
Meconium ileus | 15.00% (27)# |
First isolated P. aeruginosa | 8.55 ± 14.45 years (2 – 15 years) |
P. aeruginosa status | 56.67% (102)# |
P. aeruginosa mucoid status | 42.22% (76)# |
B. cepacia status | 13.88% (25)# |
A. xylosoxidans status | 10.00% (18)# |
S. aureus status | 78.88% (142)# |